Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety
Retrieved on:
Friday, May 6, 2022
Mental Health, Health, Genetics, General Health, Pharmaceutical, Biotechnology, 1World, Gene, Hope, COVID-19, Bipolar disorder, Genetic testing, Standard of care, Medicare, Personality disorder, Instagram, Twitter, Nasdaq, Anxiety, Health, Post-traumatic stress disorder, List of life sciences, DecisionDx-UM, Company, Panic disorder, Securities Exchange Act of 1934, Securities Act of 1933, Castle, Physician, Depression, Schizophrenia, Patient, Atopic dermatitis, Partnership, Mental Health Awareness Month, Virginia Commonwealth University, Annual report, Drug Quality and Security Act, Randomized controlled trial, Pharmacy, Precision medicine, LinkedIn, Attention deficit hyperactivity disorder, Uveal melanoma, Schrier, Education, View, Lists of diseases, Chronic pain, SEC, Mental health, Life, Awareness, Clifford Whittingham Beers, Multimedia, Miss America 2020, Pharmaceutical industry, Medicine, Facebook
The Company recently added IDgenetix, a pharmacogenomic (PGx) test for mental health conditions, to its portfolio of commercial tests.
Key Points:
- The Company recently added IDgenetix, a pharmacogenomic (PGx) test for mental health conditions, to its portfolio of commercial tests.
- Started by the Mental Health America organization in 1949, Mental Health Awareness Month is designed to help increase awareness of the importance of mental health and wellness in the U.S.
- This campaign seeks to help patients suffering from depression, anxiety and other mental health conditions to improve their chances of a beneficial medication response, Schrier continued.
- DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.